Twist Bioscience Corp (0ME.SG)
| Previous close | 33.74 |
| Open | 35.58 |
| Bid | 35.31 x 280000 |
| Ask | 35.91 x 190000 |
| Day's range | 35.40 - 35.58 |
| 52-week range | 23.83 - 118.60 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Motley Fool
3 Monster Stocks in the Making
Here's why they chose Axsome Therapeutics (NASDAQ: AXSM), Exelixis (NASDAQ: EXEL), and Twist Bioscience (NASDAQ: TWST). Prosper Junior Bakiny (Axsome Therapeutics): Many qualities are necessary to be a successful investor. The case of Axsome Therapeutics somewhat illustrates that.
- Business Wire
The Australian Research Council Centre of Excellence in Synthetic Biology and Twist Bioscience Partner to Foster and Accelerate Synthetic Biology Research in Australia
SOUTH SAN FRANCISCO, Calif. & SYDNEY, September 20, 2022--Twist Bioscience (Nasdaq: TWST) and the Australian Research Council (ARC) Centre of Excellence in Synthetic Biology (CoESB) today announced a partnership that will enable CoESB members and partners to order a wide range of Twist products that facilitate research and development.
- Business Wire
Twist Bioscience to Present at Baird 2022 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., September 06, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience will present at the Baird 2022 Global Healthcare Conference on Tuesday, September 13th, at 2:35 p.m. Eastern Time in New York, NY.
